Gabriel Cuonzo

Gabriel Cuonzo is a co-founder of Trevisan & Cuonzo and he is considered by his clients as "the go-to lawyer for challenging cases in Italy". He has a superb reputation for cutting edge multi-jurisdictional IP litigation. With over 30 years courtroom experience, Gabriel has represented many multinational companies before the Italian courts in a broad range of high profile cases with an international dimension: over the years these have included big name clients and landmark cases such as Scott Paper Company v. Kaysersberg (1994), Fujitsu v. Samsung (1997), Rambus v. Micron (2000), TRW v. Koyo (2006), Pronova v. Chiesi (2006), Ciba Vision v. Johnson & Johnson (2007), Angiotech v. Conor (2007), Novartis v. Actavis (2008), Unilever v. Nestlè (2008), Novartis v. Teva (2009), Astrazeneca v. Teva (2011), Biotec v. Novamont (2012). Bogner v. Bencom (2012), Harley-Davidson v. Pirelli (2013), Novartis v. Doc Generici (2014), Boehringer Ingelheim v. Actavis (2014), Seattle Genetics – Takeda v. Arizona State University (2015), Beiersdorf v. Neve Cosmetics (2015), Unilever v. Colgate (2015), Briggs v. Honda (2016), Boehringer Ingelheim v. Teva (2018 and 2021), Heraeus v. Zimmer Biomet (2021). With an excellent understanding of international law and as a skilled linguist, Gabriel takes a pragmatic, solution oriented approach to commercial matters and is often involved in complex, mostly IP driven, international transactions. Gabriel is widely regarded as a leading figure in pharmaceutical litigation and regulatory work.

Gabriel is a frequent speaker at international conferences. He is the author of many publications in Italian, English and German law journals in the field of intellectual property and international commercial law. He is a member of AIPPI, IBA, GRUR and INTA.